Spat between medical journals in England

Mar 16, 2007

A British medical publication has called on researchers to boycott another British medical journal, the Lancet, over its parent company's "warmongering."

"It's an unresolvable conflict that a business promoting health is making money out of a business that is damaging health," Fiona Godlee, editor of the BMJ, formerly the British Medical Journal, said in the Financial Times of the unusual boycott call to journal authors.

Reed Elsevier, the publishing group that owns the Lancet, also has an international arms fair division, which holds about 10 arms fairs per year, company spokesman Patrick Kerr said. Lancet Editor Richard Horton wrote about Reed Elsevier's weapons promotions activities in 2005, the Financial Times reported.

Kerr said Reed Elsevier respects the editorial independence of its journals, the Financial Times reported.

"We do not see any conflict between our connections with the scientific and health communities and with the legitimate defense industry trade exhibitions we run," he told the newspaper.

Copyright 2007 by United Press International

Explore further: Cambodia bans 'virgin surgery' adverts

add to favorites email to friend print save as pdf

Related Stories

China air quality dire but improving: Greenpeace

Jan 22, 2015

The skies of China's notoriously smog-filled cities saw a marginal amelioration last year, according to figures released by Greenpeace Thursday, but pollution remained far above national and international ...

Recommended for you

Cambodia bans 'virgin surgery' adverts

5 hours ago

The Cambodian government has ordered a hospital to stop advertising so-called virginity restoration procedures, saying it harms the "morality" of society.

What's happening with your donated specimen?

21 hours ago

When donating blood, plasma, human tissue or any other bodily sample for medical research, most people might not think about how it's being used. But if you were told, would you care?

Amgen tops Street 4Q forecasts

Jan 27, 2015

Amgen Inc. cruised to a 27 percent jump in fourth-quarter profit and beat Wall Street expectations, due to higher sales of nearly all its medicines, tight cost controls and a tax benefit.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.